International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
The DEA is requesting comments on the international scheduling of several new psychoactive substances, including clobromazolam, cychlorphine, desalkylgidazepam, ethylbromazolam, etomethazene, spirochlorphine, etomidate, and medetomidine, which may lead to U.S. scheduling changes.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 26, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmacies, especially those that compound or dispense controlled substances, and any business involved in the distribution or research of these substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments must be submitted by October 26, 2026 (60 days after publication).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The DEA is soliciting public comments on the international scheduling of these substances, which could lead to their placement under U.S. controlled substance schedules, imposing new regulatory requirements.
Who it affects
Pharmacies, especially those that compound or dispense controlled substances, and any business involved in the distribution or research of these substances.
What you must do
Review the list of substances and assess if your business handles any of them. If so, consider submitting comments to the DEA before the deadline and prepare for potential scheduling changes.
Deadline
Comments must be submitted by October 26, 2026 (60 days after publication).
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
- Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV
- Catina Allen, N.P.; Decision and Order
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026